More articles about Business, Policy & Funding

Koch Disruptive Technologies, Longliv Ventures, and OurCrowd participated in the round, bringing the firm's total funding to date to more than $124 million.

The tests use a range of different specimens including self-collected nasal swabs, bronchoalveolar lavage, sputum, and nasopharyngeal washes.

The genetic testing company said its orders for traditional tests have also rebounded and are on track for growth in the second half of 2020.

The company posted Q2 revenues of $13.1 million, down from $13.5 million in Q2 2019 but above the consensus Wall Street estimate of $11.8 million.

On an adjusted basis at constant exchange rates, revenues grew 19 percent year over year, in line with guidance provided by the company in early July.

Coastal Genomics owns the Ranger gel electrophoresis technology to collect specific DNA target sizes, with applications in noninvasive prenatal testing and oncology.

The firm said that its Diagnostics and Genomics segment sales were essentially flat, while its Protein Sciences segment sales were down 11 percent during Q4.

Plummeting testing for routine care activities due to COVID-19 had a negative revenue impact in all regions during the third quarter, according to the firm's CFO.

The company recorded $111,000 in revenues from its recently launched SARS-CoV-2 antibody test, which runs on its MosiaQ blood testing platform.